ESMO 2024

Escalation, De-escalation and management of therapy: how to identify the best treatment option for our patients?

New updates from the innovative I-SPY program

Therapy de-escalation and balancing individualized therapy management in early breast cancer patients

4-year update of Riboclib in EBC - can we avoid chemo?

Hypofractionation in early breast cancer

Survival benefit reported with Pembro

Registry data from France - no break in endocrine therapy in young patients

Compliance is everything

Endocrine therapy in triple-positive premenopausal patients

Physical exercise and oncological outcome

Survival data from WSG-TP-II

Overall survival advantage for Pembrolizumab in early TNBC

Evaluation of the patient collective under 40 years

Update on NATALEE in young patients

4-year landmark data

Ribociclib in younger patients

Physical exercise and oncological outcome

Update on NATALEE in young patients

De-Escalation in the metastatic setting

T-DXD for everyone - what is the minimal threshold for HER2: How to sequence therapies?

Akt-inhibition works with HR+ but not with mTNBC

Keep the patients trained!

Highlights of ESMO 2024

TILs and overall survival in the shortHER trial

Brain imaging screening in MBC patients

New approaches to treat 1L patients mTNBC

Brain imaging screening in MBC patients

PIK3CA is not a vaild pathway in triple-negative breast cancer

No benefit of Akt-inhibition in mTNBC

TILs e sopravvivenza nello studio shortHER

Punti salienti di ESMO 2024

PIK3CA is not a vaild pathway in triple-negative breast cancer

Nuovi approcci per il trattamento dei pazienti 1L mTNBC

New first choice treatment for patients with brain metastases?

Promosing results for the new ADC in HR+ - negative results for pAKT inhibitors in mTNBC: we have to better understand the biology.

Outstanding efficacy of T-Dxd in CNS meastases

Efficacy of T-Dxd in patients with brain metastasis

Soon no chemotherapy for triplenegative mBC

Endocrine-based therapy in combination with dual blockade

Optimization treatment with ADCs in endocrine therapy

Her3-Dxd - new application area for ADCs

Study impression in HR+/HER2- mBC progressing after two lines of therapy

Primary systematic treatment of active brain metastases

High sensitivity testing as outcome predictor for T-DXD in mBC

T-Dxd in BrainMets

Primary results of DB-12

HER3- DXd in the ICARUS Breast-01 study

T-Dxd in patients with and without brain metastases

ctDNA data and clinical efficacy of SG

Impression d'étude dans le cancer du sein métastatique HR+/HER2- progressant après deux lignes de traitement

Optimization treatment with ADCs in endocrine therapy

Impressione dello studio nel carcinoma mammario metastatico HR+/HER2- in progressione dopo due linee di terapia

Risultati primari dello studio DB-12

Endocrine resistance to CDK4/6 inhibitors

Screening for brain metastases – what do doctors and patients think about it?

CTCs as surrogate markers for endocrine therapy

Niraparib in ovarian cancer without survival benefit

The importance of markers for patient management

Overview on the perioperative treatment landscape

ctDNA - a promising new biomarker in early lung cancer

Neoadjuvant vs. Perioperative

BR31: The first negative adjuvant study in resected NSCLC

Perioperative IO Therapy - adjuvant necessary?

Getting rid of it will save your life!

Significant CNS protection by osimertinib

Should we move away from adjuvant immunotherapy?

Negative adjuvant CPI trial

Durvalumab did not meet primary endpoint in CCTG BR.31 trial

Eliminarlo potrebbe salvarti la vita

Durvalumab non ha raggiunto l'endpoint primario nello studio CCTG BR.31

Should we move away from adjuvant immunotherapy?

BR31: La première étude d’immunothérapie adjuvante négative dans les CBNPC réséqués

Update on genetic alterations - ALK / ROS / KRAS / BRAF

New 1st line treatment opportunities in advanced stage NSCLC

Pieces of evidence in the EGFR domain

MARIPOSA - lower rate of MET amplification and EGFR resistance mutation

Quality of life with Telisotuzumab in LUMINOSITY

NVALT: 1st attempt to reduce dose of pembrolizumab and limit the financial burden

1st line encorafenib + binimetinib: combination is very active but PFS very different

Sustained OS at 2nd interim analysis in MARIPOSA-2

Second interim analysis of MARIPOSA-2

Survival Data with Amivantamab for EGFR Alteration

NVL-520 for ROS alteration - already best in class?

Promising signal for anti-TIGIT + anti-PD-1 with PD-L1 > 50 %

4th generation with ALK-alterations

Bispecific antibodies better than ADCs?

The next generation of ROS inhibitors

Half of the dose - same activity: provocative findings from NVALT-30

NVL-655: a promising new ALK inhibitor

Adding anti-LAG-3 doesn't seem to being worth it

The next generation of ALK inhibitors

Optimizing the dose of immunotherapy

RELATIVITY-104: efficacy of anti immunotherapy

Two sometimes may be better than one!

Early mechanisms of resistance from MARIPOSA

Patterns of resistance in MARIPOSA trial

Optimizing the dose of immunotherapy

2 a volte sono meglio di uno

Patterns of resistance in MARIPOSA trial

NVALT: Première tentative pour réduire la dose de pembrolizumab dans les CBNPC de stade IV et réduire le cout du traitement

CBNPC muté BRAF en 1ère ligne : encorafenib + binimetinib : association très active mais la SSP très différente selon les études

RELATIVITY-104: efficacy of anti immunotherapy

Quality of life with Telisotuzumab in LUMINOSITY

Second interim analysis of MARIPOSA-2

Aggiungere l'anti-LAG-3 non sembra valerne la pena

New data on SCLC and mesothelioma

New standard of care in LS-SCLC

Subset analysis from ADRIATIC

Neuer Behandlungsstandard beim LS-SCLC

Response assessment in mesothelioma - can AI help?

Is the radiologist redundant in mesothelioma RECIST measurements

Is the radiologist redundant in mesothelioma RECIST measurements

Practice changing- Big Revival - Or just a Splish? Don't forget the bone protection!

Doublet therapy in prostate cancer: Practice changing or rather practice informing?

IO in mCRPC: Let's move on to the next substance?!

New hormone therapy for mCRPC

Molecular analysis from PEACE-1

Did CONTACT make any contact?

Metformin in mHSPC

Not a Patch on ADT?

PSMA-radioligand - the first study of its kind

Darolutamide in mHSPC

Radium-223 an option again?

Was it a splash or was it a splish?

Radium223 Prior to Docetaxel Improves Quality of Life in Bone-Dominant mCRPC: Findings from the RAPSON Phase 2 Trial

New PSMA-ligand

We come in PEACE

LuPSMA moves UpFront

Immunotherapy for prostate cancer

Radium and enzalutamide in mCRPC - final results

Upfronts in personal

New PSMA-ligand

Radium and enzalutamide in mCRPC - final results

Molecular analysis from PEACE-1

PSMA-radioligand - the first study of its kind

Microbiome transplantation in RCC – how to tailor this therapy for our patients

IO after IO – is there a role for sequential immunotherapy in RCC?

Where is the right place for HIF inhibitors in advanced RCC therapy?

Establishing ICI as standard of care in RCC

Sequencing checkpoint inhibitors - the story is over

Ipi-Nivo in nccRCC

Glycoproteins as Predictive Biomarkers for Nivolumab Plus Cabozantinib Response in Advanced Renal Cell Carcinoma

SUNNIFORECAST - rain or shine?

IO therapy is standard for nccRCC

My view on SUNNIFORECAST

The role of sequencing therapy in RCC

Opening a new way of treatment in MIBC

mRCC ≥ 1L? News on intensification?

New SOC for non-cc-RCC?

Treating nccRCC - Nivo/Ipi as a new potential option

TKI monotherapy remains standard in 2ndL

HIF-2a inhibitors are on their way

CPI - modification / prediction - fact or fantasy?

FMT in a novel setting

Stool transplantation is the shit

Immunotherapy for nccRCC

Updated survival results

Tratamiento del nccRCC - Nivo/Ipi como nueva opción potencial

Sequencing checkpoint inhibitors - the story is over

Se abre una nueva vía de tratamiento en el cáncer de vejiga con invasión muscular

Biomarkers in Bladder cancer - the road to individualized therapy

Chemo + IO in the perioperative setting - new standard of care

Encouraging data - but we need more data!

Is intravesical therapy as easy as baking a pretzel?

TAR200 intravesical +/- Cetrelimab in HR (N)MIBC

Nivolumab Plus Gemcitabine-Cisplatin Maintains Quality of Life in Metastatic Urothelial Carcinoma

Practice changing new data in Bladder cancer at ESMO24

New data on ADCs in bladder cancer

Pretzel therapy for superficial UC

New standard: perioperative MIBC-NIAGARA

A new way to give chemo for patients who are ineligible for neoadj therapy

NIAGARA sets new standard

mUC - new ADC's?

EV + Pembro is broadly effective

Value of ctDNA

Practice changing new data in Bladder cancer at ESMO24

Nuevos datos sobre las ADC en el cáncer de vejiga

A new way to give chemo for patients who are ineligible for neoadj therapy